%0 Journal Article
%A Dam, Tien
%A Boxer, Adam L
%A Golbe, Lawrence I
%A Höglinger, Günter
%A Morris, Huw R
%A Litvan, Irene
%A Lang, Anthony E
%A Corvol, Jean-Christophe
%A Aiba, Ikuko
%A Grundman, Michael
%A Yang, Lili
%A Tidemann-Miller, Beth
%A Kupferman, Joseph
%A Harper, Kristine
%A Kamisoglu, Kubra
%A Wald, Michael J
%A Graham, Danielle L
%A Gedney, Liz
%A O'Gorman, John
%A Haeberlein, Samantha Budd
%T Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.
%J Nature medicine
%V 27
%N 8
%@ 1546-170X
%C New York, NY
%I Nature America Inc.
%M DZNE-2021-01399
%P 1451 - 1457
%D 2021
%X A randomized, double-blind, placebo-controlled, 52-week study (no. NCT03068468) evaluated gosuranemab, an anti-tau monoclonal antibody, in the treatment of progressive supranuclear palsy (PSP). In total, 486 participants dosed were assigned to either gosuranemab (n = 321) or placebo (n = 165). Efficacy was not demonstrated on adjusted mean change of PSP Rating Scale score at week 52 between gosuranemab and placebo (10.4 versus 10.6, P = 0.85, primary endpoint), or at secondary endpoints, resulting in discontinuation of the open-label, long-term extension. Unbound N-terminal tau in cerebrospinal fluid decreased by 98
%K Aged
%K Antibodies, Monoclonal, Humanized: adverse effects
%K Antibodies, Monoclonal, Humanized: therapeutic use
%K Double-Blind Method
%K Female
%K Humans
%K Male
%K Pneumonia: etiology
%K Supranuclear Palsy, Progressive: drug therapy
%K Treatment Outcome
%K tau Proteins: immunology
%K Antibodies, Monoclonal, Humanized (NLM Chemicals)
%K MAPT protein, human (NLM Chemicals)
%K tau Proteins (NLM Chemicals)
%K gosuranemab (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:34385707
%R 10.1038/s41591-021-01455-x
%U https://pub.dzne.de/record/162743